Patents/Assignees

Novartis AG

240 patents in portfolio

US11702409utility2023
Pyrazolyl Derivatives Useful as Anti-cancer Agents
0 cites
US11692046utility2023
FGF21 Mimetic Antibodies and Uses Thereof
0 cites
US11685776utility2023
Engineered Heterodimeric Proteins
0 cites
US11679028utility2023
Multi-dose Ocular Fluid Delivery System
0 cites
US11672782utility2023
Carboxamide Derivatives
0 cites
US11672799utility2023
1,4-disubstituted Pyridazine Quinolne Analogs There of and Methods for Treating Smn-deficiency-related Conditions
0 cites
US11673868utility2023
Amino Pyrimidine Derivatives
0 cites
US11648253utility2023
Thienopyrimidinone NMDA Receptor Modulators and Uses Thereof
0 cites
US11642315utility2023
Method for Preparing a Pharmaceutical Product
0 cites
US11639378utility2023
Polyomavirus Neutralizing Antibodies
0 cites
US11634497utility2023
Anti-ccr7 Antibody Drug Conjugates
0 cites
US11628137utility2023
Parenteral Formulation Comprising Siponimod
0 cites
US11629124utility2023
Solid Forms Comprising an Oxime Ether Compound, Compositions and Methods of Use Thereof
0 cites
US11629149utility2023
10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza
0 cites
US11612659utility2023
Anti-cd40 Antibody Formulation Delivery Device
0 cites
US11613543utility2023
Substituted Pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase Inhibitors
0 cites
US11607486utility2023
Injector Device
0 cites
US11608382utility2023
BCMA Chimeric Antigen Receptors and Uses Thereof
0 cites
US11603363utility2023
Crystalline Form of LNP023
0 cites
US11596695utility2023
Specific Sites for Modifying Antibodies to Make Immunoconjugates
0 cites

← PreviousPage 11 of 12Next →